Suzhou-based biopharmaceutical company Ascentage Pharma Group International has filed for an initial public offering in Hong Kong, according to its IPO prospectus. Following Hangzhou-based Ascletis Pharma, Ascentage Pharma has become another biotech firm to exploit Hong Kong’s new and more accommodating listing rules amended in April. The new rules permit listings of biotech companies that do not meet the Main Board’s financial eligibility tests. Ascentage Pharma is a clinical-stage biotechnology firm engaged in developing novel therapies for cancers, hepatitis B …

Oriza-backed Chinese Biotechnology Firm Ascentage Pharma Files For Hong Kong IPO appeared first on China Money Network.